Role of inflammatory cytokines in depression: Focus on interleukin-1β (Review)

  • Authors:
    • Rai Khalid Farooq
    • Kashif Asghar
    • Shahzina Kanwal
    • Ali Zulqernain
  • View Affiliations

  • Published online on: November 10, 2016     https://doi.org/10.3892/br.2016.807
  • Pages: 15-20
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

According to the World Health Organization, major depression will become the leading cause of disability worldwide by the year 2030. Despite extensive research into the mechanisms underlying this disease, the rate, prevalence and disease burden has been on the rise, particularly in the industrialized world. Epidemiological studies have shown biological and biochemical differences in disease characteristics and treatment responses in different age groups. Notable differences have been observed in the clinical presentation, co‑prevalence with other diseases, interaction with the immune system and even in the outcome. Thus, there is an increased interest in characterizing these differences, particularly in terms of contribution of different factors, including age, cytokines and immunotherapy. Research into the possible mechanisms of these interactions may reveal novel opportunities for future pharmacotherapy. The aim of the present review is to document recent literature regarding the impact of inflammatory mechanisms on the pathophysiology of the depressive disorder.

References

1 

Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 3:e4422006. View Article : Google Scholar : PubMed/NCBI

2 

Seligman ME and Csikszentmihalyi M: Positive psychology: an introduction. Springer. Netherlands, Dordrecht: 279–298. 2014.

3 

Murphy DL, Cohen RM, Siever LJ, Roy B, Karoum F, Wyatt RJ, Garrick NA and Linnoila M: Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. Mod Probl Pharmacopsychiatry. 19:287–303. 1983. View Article : Google Scholar : PubMed/NCBI

4 

Ader R and Cohen N: High time for psychoimmunology. Nature. 315:103–104. 1985. View Article : Google Scholar : PubMed/NCBI

5 

Maes M: Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry. 19:11–38. 1995. View Article : Google Scholar : PubMed/NCBI

6 

Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P and Leonard B: Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med. 10:662012. View Article : Google Scholar : PubMed/NCBI

7 

Skaper SD, Facci L and Giusti P: Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets. 13:1654–1666. 2014. View Article : Google Scholar : PubMed/NCBI

8 

Maes M, Van de Vyvere J, Vandoolaeghe E, Bril T, Demedts P, Wauters A and Neels H: Alterations in iron metabolism and the erythron in major depression: Further evidence for a chronic inflammatory process. J Affect Disord. 40:23–33. 1996. View Article : Google Scholar : PubMed/NCBI

9 

Smith RS: The macrophage theory of depression. Med Hypotheses. 35:298–306. 1991. View Article : Google Scholar : PubMed/NCBI

10 

Patel A: Review: The role of inflammation in depression. Psychiatr Danub. 25:(Suppl 2). S216–S223. 2013.PubMed/NCBI

11 

Dantzer R: Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am. 29:247–264. 2009. View Article : Google Scholar : PubMed/NCBI

12 

Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev. 12:123–137. 1988. View Article : Google Scholar : PubMed/NCBI

13 

Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ and Vannice JL: Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA. 89:9117–9120. 1992. View Article : Google Scholar : PubMed/NCBI

14 

Raison CL, Capuron L and Miller AH: Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 27:24–31. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Irwin M: Immune correlates of depression. Adv Exp Med Biol. 461:1–24. 1999. View Article : Google Scholar : PubMed/NCBI

16 

Cruess DG, Douglas SD, Petitto JM, Have TT, Gettes D, Dubé B, Cary M and Evans DL: Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry. 162:2125–2130. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, Brinker-Spence P, Job C, Mercer DE, Wang YL, et al: Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry. 159:1752–1759. 2002. View Article : Google Scholar : PubMed/NCBI

18 

Pike JL and Irwin MR: Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun. 20:169–174. 2006. View Article : Google Scholar : PubMed/NCBI

19 

Papanicolaou DA, Wilder RL, Manolagas SC and Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med. 128:127–137. 1998. View Article : Google Scholar : PubMed/NCBI

20 

Liu Y, Ho RC and Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord. 139:230–239. 2012. View Article : Google Scholar : PubMed/NCBI

21 

Brebner K, Hayley S, Zacharko R, Merali Z and Anisman H: Synergistic effects of interleukin-1β, interleukin-6, and tumor necrosis factor-α: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology. 22:566–580. 2000. View Article : Google Scholar : PubMed/NCBI

22 

Yudkin JS, Kumari M, Humphries SE and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis. 148:209–214. 2000. View Article : Google Scholar : PubMed/NCBI

23 

Carvalho LA, Urbanova L, Hamer M, Hackett RA, Lazzarino AI and Steptoe A: Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology. 51:209–218. 2015. View Article : Google Scholar : PubMed/NCBI

24 

McInnis CM, Thoma MV, Gianferante D, Hanlin L, Chen X, Breines JG, Hong S and Rohleder N: Measures of adiposity predict interleukin-6 responses to repeated psychosocial stress. Brain Behav Immun. 42:33–40. 2014. View Article : Google Scholar : PubMed/NCBI

25 

Ershler WB and Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med. 51:245–270. 2000. View Article : Google Scholar : PubMed/NCBI

26 

Windham BG, Simpson BN, Lirette S, Bridges J, Bielak L, Peyser PA, Kullo I, Turner S, Griswold ME and Mosley TH: Associations between inflammation and cognitive function in African Americans and European Americans. J Am Geriatr Soc. 62:2303–2310. 2014. View Article : Google Scholar : PubMed/NCBI

27 

Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 19:2364–2367. 1999. View Article : Google Scholar : PubMed/NCBI

28 

Zhang T, Chen Y, Liu H, Zhou Z, Zhai Y and Yang J: Chronic unpredictable stress accelerates atherosclerosis through promoting inflammation in apolipoprotein E knockout mice. Thromb Res. 126:386–392. 2010. View Article : Google Scholar : PubMed/NCBI

29 

Song C, Dinan T and Leonard BE: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord. 30:283–288. 1994. View Article : Google Scholar : PubMed/NCBI

30 

Yudkin JS, Yajnik CS, Mohamed-Ali V and Bulmer K: High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians. A potential explanation for increased risk of diabetes and coronary heart disease. Diabetes Care. 22:363–364. 1999. View Article : Google Scholar : PubMed/NCBI

31 

Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, Chrousos GP and Geracioti TD Jr: Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation. 9:209–217. 2001. View Article : Google Scholar : PubMed/NCBI

32 

Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR and Maier SF: Exposure to acute stress induces brain interleukin-1β protein in the rat. J Neurosci. 18:2239–2246. 1998.PubMed/NCBI

33 

Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M and Barak V: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 40:171–176. 1999. View Article : Google Scholar : PubMed/NCBI

34 

Prolla TA: DNA microarray analysis of the aging brain. Chem Senses. 27:299–306. 2002. View Article : Google Scholar : PubMed/NCBI

35 

Choi SH and Suh KY: Interleukin-1 beta,-2,-6 production, serum concentration and hypothalamic-pituitary-adrenal axis in patients with major depression. J Korean Neuropsychiatr Assoc. 37:537–547. 1998.

36 

Thomas AJ, Davis S, Morris C, Jackson E, Harrison R and O'Brien JT: Increase in interleukin-1β in late-life depression. Am J Psychiatry. 162:175–177. 2005. View Article : Google Scholar : PubMed/NCBI

37 

Corwin EJ, Johnston N and Pugh L: Symptoms of postpartum depression associated with elevated levels of interleukin-1 beta during the first month postpartum. Biol Res Nurs. 10:128–133. 2008. View Article : Google Scholar : PubMed/NCBI

38 

Ovaskainen Y, Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E and Vanhala M: Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res. 167:73–79. 2009. View Article : Google Scholar : PubMed/NCBI

39 

Cousins RJ and Leinart AS: Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. FASEB J. 2:2884–2890. 1988.PubMed/NCBI

40 

Nolan Y, Maher FO, Martin DS, Clarke RM, Brady MT, Bolton AE, Mills KH and Lynch MA: Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J Biol Chem. 280:9354–9362. 2005. View Article : Google Scholar : PubMed/NCBI

41 

O'Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, O'Farrelly C and Malone KM: Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety. 30:307–314. 2013. View Article : Google Scholar : PubMed/NCBI

42 

Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J, Palha JA and Sousa N: IL-10 modulates depressive-like behavior. J Psychiatr Res. 43:89–97. 2008. View Article : Google Scholar : PubMed/NCBI

43 

Ledeboer A, Brevé JJ, Wierinckx A, van der Jagt S, Bristow AF, Leysen JE, Tilders FJ and Van Dam AM: Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur J Neurosci. 16:1175–1185. 2002. View Article : Google Scholar : PubMed/NCBI

44 

Ledeboer A, Brevé JJ, Poole S, Tilders FJ and Van Dam AM: Interleukin-10, interleukin-4, and transforming growth factor-β differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia. 30:134–142. 2000. View Article : Google Scholar : PubMed/NCBI

45 

Streit WJ, Sammons NW, Kuhns AJ and Sparks DL: Dystrophic microglia in the aging human brain. Glia. 45:208–212. 2004. View Article : Google Scholar : PubMed/NCBI

46 

Kelley KW, O'Connor JC, Lawson MA, Dantzer R, Rodriguez-Zas SL and McCusker RH: Aging leads to prolonged duration of inflammation-induced depression-like behavior caused by Bacillus Calmette-Guérin. Brain Behav Immun. 32:63–69. 2013. View Article : Google Scholar : PubMed/NCBI

47 

Isingrini E, Desmidt T, Belzung C and Camus V: Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer's disease? Curr Opin Investig Drugs. 10:46–55. 2009.PubMed/NCBI

48 

Rotheneichner P, Lange S, O'Sullivan A, Marschallinger J, Zaunmair P, Geretsegger C, Aigner L and Couillard-Despres S: Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast. 2014:7239152014.PubMed/NCBI

49 

Koo JW and Duman RS: IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA. 105:751–756. 2008. View Article : Google Scholar : PubMed/NCBI

50 

Samuels BA, Mendez-David I, Faye C, David SA, Pierz KA, Gardier AM, Hen R and David DJ: Serotonin 1A and serotonin 4 receptors: Essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist. 22:26–45. 2016. View Article : Google Scholar : PubMed/NCBI

51 

Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH and Ganapathy V: Regulation of the human serotonin transporter by interleukin-1 β. Biochem Biophys Res Commun. 216:560–567. 1995. View Article : Google Scholar : PubMed/NCBI

52 

Linthorst AC, Flachskamm C, Müller-Preuss P, Holsboer F and Reul JM: Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: An in vivo microdialysis study. J Neurosci. 15:2920–2934. 1995.PubMed/NCBI

53 

Linthorst AC, Flachskamm C, Holsboer F and Reul JM: Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology. 135:520–532. 1994. View Article : Google Scholar : PubMed/NCBI

54 

Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, Yagi G, Kato R and Asai M: Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci. 13:3574–3581. 1993.PubMed/NCBI

55 

Zhu CB, Blakely RD and Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology. 31:2121–2131. 2006.PubMed/NCBI

56 

Sperlágh B, Vizi ES, Wirkner K and Illes P: P2X7 receptors in the nervous system. Prog Neurobiol. 78:327–346. 2006. View Article : Google Scholar : PubMed/NCBI

57 

Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB and Malcangio M: P2X7-dependent release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide. J Neurosci. 30:573–582. 2010. View Article : Google Scholar : PubMed/NCBI

58 

Seil M, El Ouaaliti M, Foumekoye S Abdou, Pochet S and Dehaye JP: Distinct regulation by lipopolysaccharides of the expression of interleukin-1β by murine macrophages and salivary glands. Innate Immun. 18:14–24. 2012. View Article : Google Scholar : PubMed/NCBI

59 

Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A and Jiang LH: Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res. 44:347–355. 2010. View Article : Google Scholar : PubMed/NCBI

60 

Andó R, Gölöncsér F and Sperlágh B: Modulation of P2X7 receptor function alters depressive behavior in rodent models of depression. Front Neurosci Conference Abstract: IBRO International Workshop 2010. 2010.

61 

Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW and Rueter LE: Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders. Behav Brain Res. 198:83–90. 2009. View Article : Google Scholar : PubMed/NCBI

62 

Lawson MA, McCusker RH and Kelley KW: Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J Neuroinflammation. 10:542013. View Article : Google Scholar : PubMed/NCBI

63 

Leutscher PDC, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S, Hellstrand K, et al: NORDynamIC Group: Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology. 52:430–435. 2010. View Article : Google Scholar : PubMed/NCBI

64 

Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, Cella D and Trikha M: Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol. 3:37–50. 2005.PubMed/NCBI

65 

Xia Z, DePierre JW and Nässberger L: Tricyclic antidepressants inhibit IL-6, IL-1 β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology. 34:27–37. 1996. View Article : Google Scholar : PubMed/NCBI

66 

Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB and Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 344:961–966. 2001. View Article : Google Scholar : PubMed/NCBI

67 

Lanquillon S, Krieg JC, Bening-Abu-Shach U and Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology. 22:370–379. 2000. View Article : Google Scholar : PubMed/NCBI

68 

Trask PC, Esper P, Riba M and Redman B: Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol. 18:2316–2326. 2000.PubMed/NCBI

69 

Yates WR and Gleason O: Hepatitis C and depression. Depress Anxiety. 7:188–193. 1998. View Article : Google Scholar : PubMed/NCBI

70 

Scheibel RS, Valentine AD, O'Brien S and Meyers CA: Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci. 16:185–191. 2004. View Article : Google Scholar : PubMed/NCBI

71 

Gitlin N: Hepatitis B: Diagnosis, prevention, and treatment. Clin Chem. 43:1500–1506. 1997.PubMed/NCBI

72 

Horsmans Y: Chronic hepatitis C, depression and interferon. J Hepatol. 42:788–789. 2005. View Article : Google Scholar : PubMed/NCBI

73 

Lotrich FE, Rabinovitz M, Gironda P and Pollock BG: Depression following pegylated interferon-alpha: Characteristics and vulnerability. J Psychosom Res. 63:131–135. 2007. View Article : Google Scholar : PubMed/NCBI

74 

Koprich JB, Reske-Nielsen C, Mithal P and Isacson O: Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease. J Neuroinflammation. 5:82008. View Article : Google Scholar : PubMed/NCBI

75 

Sulaiman AH, Zainal NZ, Tan KS and Tan CT: Prevalence and associations of post-stroke depression. Neurol J Southeast Asia. 7:71–75. 2002.

76 

Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR and Evans JJ: Depression and anxiety symptoms post-stroke/TIA: Prevalence and associations in cross-sectional data from a regional stroke registry. BMC Neurol. 14:1982014. View Article : Google Scholar : PubMed/NCBI

77 

Ojagbemi A, Owolabi M, Atalabi M and Baiyewu O: Stroke lesions and post-stroke depression among survivors in Ibadan, Nigeria. Afr J Med Med Sci. 42:245–251. 2013.PubMed/NCBI

78 

Herrmann N, Black SE, Lawrence J, Szekely C and Szalai JP: The Sunnybrook Stroke Study: A prospective study of depressive symptoms and functional outcome. Stroke. 29:618–624. 1998. View Article : Google Scholar : PubMed/NCBI

79 

Herrmann LL, Le Masurier M and Ebmeier KP: White matter hyperintensities in late life depression: A systematic review. J Neurol Neurosurg Psychiatry. 79:619–624. 2008. View Article : Google Scholar : PubMed/NCBI

80 

Huang J, Upadhyay UM and Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol. 66:232–245. 2006. View Article : Google Scholar : PubMed/NCBI

81 

Wiart M, Davoust N, Pialat J-B, Desestret V, Moucharrafie S, Cho TH, Mutin M, Langlois JB, Beuf O, Honnorat J, et al: MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke. 38:131–137. 2007. View Article : Google Scholar : PubMed/NCBI

82 

Tynan RJ, Naicker S, Hinwood M, Nalivaiko E, Buller KM, Pow DV, Day TA and Walker FR: Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun. 24:1058–1068. 2010. View Article : Google Scholar : PubMed/NCBI

83 

Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B and Maj M: The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis. 24:27–53. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

January 2017
Volume 6 Issue 1

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Farooq, R.K., Asghar, K., Kanwal, S., & Zulqernain, A. (2017). Role of inflammatory cytokines in depression: Focus on interleukin-1β (Review). Biomedical Reports, 6, 15-20. https://doi.org/10.3892/br.2016.807
MLA
Farooq, R. K., Asghar, K., Kanwal, S., Zulqernain, A."Role of inflammatory cytokines in depression: Focus on interleukin-1β (Review)". Biomedical Reports 6.1 (2017): 15-20.
Chicago
Farooq, R. K., Asghar, K., Kanwal, S., Zulqernain, A."Role of inflammatory cytokines in depression: Focus on interleukin-1β (Review)". Biomedical Reports 6, no. 1 (2017): 15-20. https://doi.org/10.3892/br.2016.807